Pierre Fabre Selects AGC Biologics as CDMO to manufacture the orphan drug ER-004
Pierre Fabre and the EspeRare Foundation administer investigational treatment to first patient in EDELIFE clinical trial for rare genetic disease, XLHED
EspeRare partners its XLHED program with Pierre Fabre | EspeRare Foundation
Have a beautiful skin with our 8 expert brands | Pierre Fabre
Pierre Fabre is supporting “Les Bacchantes”;
T-shirt Pierre Fabre Castres
Have a beautiful skin with our 8 expert brands | Pierre Fabre
Have a beautiful skin with our 8 expert brands | Pierre Fabre
Pierre Fabre is supporting “Les Bacchantes”;
Stade Pierre Fabre Castres - Pop And Kop
EspeRare & Pierre Fabre | A pioneering treatment for XLHED - BioAlps
Have a beautiful skin with our 8 expert brands | Pierre Fabre
Sweat à capuche - Rugby - Castres - Hémisphère Nord
Sweat à capuche - Rugby - Castres - Hémisphère Nord
Have a beautiful skin with our 9 expert brands | Pierre Fabre
Pierre Fabre is taking a minority stake, via its dedicated investment subsidiary Pierre Fabre Invest, in Gennisium Pharma, an innovative company speci
The EspeRare Foundation and Pierre Fabre join forces to develop and market a pioneering treatment for XLHED, a dermatologic-related rare genetic disease that requires prenatal therapeutic intervention
